Strata Skin Sciences (SSKN) has provided an update.
STRATA Skin Sciences, Inc. revealed preliminary financial figures for Q2 2024, with revenues expected between $8.0 million to $8.4 million, despite a slight decrease in its XTRAC® device installations. In contrast, installations of TheraClear®X devices showed growth, and the company ended the quarter with $6.8 million in cash and equivalents. The report also contains forward-looking statements, advising investors of potential risks and urging them to review further disclosures for a more informed perspective.
For an in-depth examination of SSKN stock, go to TipRanks’ Stock Analysis page.
